Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 6/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17092148 | 0.80 | PLAT (0.41) | PLATBTKGABRA1GABRB2IKBKB | |
| SCHEMBL5787073 | 0.68 | ALDH1A1 (0.54) | GABRA1GABRB2RORCMEN1GAA | |
| Hydrochloric Acid SCHEMBL5785892 | 0.67 | ALDH1A1 (0.52) | GABRA1GABRB2RORCMEN1GAA | |
| SCHEMBL16597770 | 0.66 | BTK (0.50) | BTKGABRA1GABRG2GABRB3 | |
| Biphenyl SCHEMBL28463058 | 0.64 | SMN1; SMN2 (0.54) | PLATGABRA1GABRB2IKBKBCHUK | |
| SCHEMBL15647257 | 0.63 | PRMT5 (0.42) | GABRA1GABRB2IKBKBCHUKPARP1 | |
| SCHEMBL1428165 | 0.62 | NR1H2 (0.47) | GABRA1GABRB2MEN1KMT2A | |
| SCHEMBL17857656 | 0.62 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL4664929 | 0.62 | IKBKB (0.65) | BTKIKBKBCHUK | |
| SCHEMBL17837506 | 0.62 | PARP1 (0.41) | PLATBTKPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | PLAT 4745/4885BTK 2343/4885GABRA1 482/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | PLAT 4821/4885BTK 2023/4885GABRA1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.